Adjuvant Semaglutide and Tirzepatide Significantly Improve 10-Year Weight Loss After Sleeve Gastrectomy
Background
Maintaining long-term weight loss after bariatric surgery, particularly sleeve gastrectomy (SG), remains a significant challenge for many patients with class II-III obesity. While SG is highly effective initially, weight regain can occur over time, diminishing its metabolic benefits. Current standard-of-care often lacks robust strategies for sustained weight management beyond the initial postoperative period. This study addresses the gap by investigating whether the adjunctive use of modern anti-obesity medications (AOMs) like GLP-1 receptor agonists can optimize long-term weight outcomes, even when initiated years after surgery.
Study Design
This retrospective, single-institution study analyzed 111 adult patients who underwent sleeve gastrectomy between January 2013 and December 2014, specifically those under 45 years old at the time of surgery. Inclusion required BMI data available at least 9.5 years post-SG, with patients undergoing conversion to RYGB excluded. Researchers compared longitudinal weight loss outcomes between two groups: 44 patients taking adjuvant semaglutide and/or tirzepatide for at least 1 year at their most recent visit, and 67 patients not taking any adjuvant AOMs.
Results
Among the 111 included patients, a significant difference in long-term weight loss was observed. Patients not taking adjuvant AOMs achieved a mean percent total weight loss (%TWL) of 14.1% at a mean of 10.6 years after SG. In stark contrast, patients taking adjuvant AOMs (comprising 29 on semaglutide and 15 on tirzepatide) demonstrated a mean %TWL of 25.7% at a mean of 10.7 years post-SG.
This represents an 11.6% absolute difference in %TWL, which was statistically highly significant (p < 0.001). Notably, patients in the AOM group typically initiated their medications an average of 7.6 years after SG and had been taking them for an average of 3.0 years at the time of their most recent follow-up. Both groups exhibited similar weight loss trajectories prior to the initiation of adjuvant medications, suggesting the observed difference was attributable to the AOMs.
Key Findings
- Patients on adjuvant AOMs achieved 25.7% mean total weight loss at 10.7 years post-SG.
- Patients not on adjuvant AOMs achieved 14.1% mean total weight loss at 10.6 years post-SG.
- Adjuvant AOMs resulted in an 11.6% greater %TWL compared to no AOMs (p < 0.001).
- AOMs were initiated an average of 7.6 years after SG and taken for 3.0 years.
Why It Matters
This study provides compelling evidence that adjuvant semaglutide and tirzepatide can significantly improve long-term weight loss maintenance after sleeve gastrectomy, even when started many years post-operation. For individuals who experience weight regain after bariatric surgery, this suggests a powerful therapeutic option to re-engage weight loss and sustain metabolic benefits. Clinicians should consider integrating AOMs into long-term post-bariatric care protocols, recognizing their potential to rescue and optimize outcomes years after the initial surgery. This finding is particularly relevant for biohackers and individuals managing weight, highlighting that these peptides are not just for initial weight loss but can be crucial tools for long-term management in complex scenarios.
semaglutide
tirzepatide
sleeve-gastrectomy
obesity
weight-loss
long-term-outcomes